Literature DB >> 28507393

Treating patients on new anticoagulant drugs.

Shyan Goh1.   

Abstract

Entities:  

Year:  2017        PMID: 28507393      PMCID: PMC5407993          DOI: 10.18773/austprescr.2017.021

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


× No keyword cloud information.
  7 in total

Review 1.  Long-term prescribing of new oral anticoagulants.

Authors:  Paul Kl Chin; Matthew P Doogue
Journal:  Aust Prescr       Date:  2016-12-05

2.  An update of consensus guidelines for warfarin reversal.

Authors:  Huyen A Tran; Sanjeev D Chunilal; Paul L Harper; Huy Tran; Erica M Wood; Alex S Gallus
Journal:  Med J Aust       Date:  2013-03-04       Impact factor: 7.738

3.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

4.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

5.  Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Authors:  Sam Schulman; Ajay K Kakkar; Samuel Z Goldhaber; Sebastian Schellong; Henry Eriksson; Patrick Mismetti; Anita Vedel Christiansen; Jeffrey Friedman; Florence Le Maulf; Nuala Peter; Clive Kearon
Journal:  Circulation       Date:  2013-12-16       Impact factor: 29.690

Review 6.  A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.

Authors:  Paul K L Chin; Daniel F B Wright; David M Patterson; Matthew P Doogue; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

7.  Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

Authors:  Stephan Glund; Joachim Stangier; Joanne van Ryn; Michael Schmohl; Viktoria Moschetti; Wouter Haazen; Marina De Smet; Dietmar Gansser; Stephen Norris; Benjamin Lang; Paul Reilly; Jörg Kreuzer
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.